Aravax
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
15
11 to 50 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Aravax
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- AH
Andrew Humberstone
Director Clinical Development · Research & Development
EmailPhone - AL
Annette Leahy
Director Clinical Operations · Operations
EmailPhone - AW
Aled Williams
Chief Business Officer (Cbo) · General Business & Management
EmailPhone - SP
Sara Prickett
Director and Founder · General Business & Management
EmailPhone
Showing 4 of 5 verified contacts
Top roles at Aravax
5 distinct titles indexed · top 5 shown.
- 1chief business officer (cbo)
- 1director and founder
- 1director clinical development
- 1director clinical operations
- 1vice president, pharmaceutical development
Sign up to unlock all 5 contacts at Aravax
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Aravax
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.